Assenagon Asset Management
CTMX icon

Assenagon Asset Management’s CytomX Therapeutics CTMX Stock Holding History

Assenagon Asset Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.37M Hold
364,173
– – ﹤0.01% 921
2026
Q1 		$1.71M Sell
364,173
-228,523
-39% -$1.16M ﹤0.01% 800
2025
Q4 		$2.52M Sell
592,696
-137,271
-19% -$521K ﹤0.01% 794
2025
Q3 		$2.33M Buy
729,967
+9,947
+1% +$22.4K ﹤0.01% 797
2025
Q2 		$1.63M Buy
720,020
+8,566
+1% +$13.8K ﹤0.01% 820
2025
Q1 		$452K Buy
711,454
+111,604
+19% +$86.5K ﹤0.01% 1030
2024
Q4 		$618K Sell
599,850
-1,044,318
-64% -$1.12M ﹤0.01% 1171
2024
Q3 		$1.94M Buy
1,644,168
+405,669
+33% +$515K ﹤0.01% 977
2024
Q2 		$1.51M Buy
1,238,499
+833,825
+206% +$1.66M ﹤0.01% 989
2024
Q1 		$882K Hold
404,674
– – ﹤0.01% 1082
2023
Q4 		$627K Sell
404,674
-21,247
-5% -$27.9K ﹤0.01% 1211
2023
Q3 		$549K Sell
425,921
-242,111
-36% -$381K ﹤0.01% 1181
2023
Q2 		$1.15M Hold
668,032
– – ﹤0.01% 937
2023
Q1 		$1.01M Sell
668,032
-246,868
-27% -$558K ﹤0.01% 1045
2022
Q4 		$1.46M Sell
914,900
-150,492
-14% -$223K 0.01% 936
2022
Q3 		$1.54M Buy
+1,065,392
New +$1.64M 0.01% 787
2021
Q4 		– Sell
-27,774
Closed -$141K – 1452
2021
Q3 		$141K Sell
27,774
-465,239
-94% -$2.49M ﹤0.01% 1250
2021
Q2 		$3.12M Buy
493,013
+288,872
+142% +$2.25M 0.01% 587
2021
Q1 		$1.58M Sell
204,141
-14,622
-7% -$116K 0.01% 771
2020
Q4 		$1.43M Buy
218,763
+45,887
+27% +$328K 0.01% 618
2020
Q3 		$1.15M Sell
172,876
-80,824
-32% -$599K 0.01% 756
2020
Q2 		$2.11M Buy
+253,700
New +$2.36M 0.01% 578
2020
Q1 		– Sell
-224,640
Closed -$1.87M – 830
2019
Q4 		$1.87M Buy
224,640
+148,740
+196% +$1M 0.01% 457
2019
Q3 		$560K Sell
75,900
-48,500
-39% -$478K ﹤0.01% 679
2019
Q2 		$1.4M Buy
+124,400
New +$1.3M 0.01% 632
2018
Q4 		– Sell
-19,638
Closed -$363K – 1026
2018
Q3 		$363K Buy
+19,638
New +$447K ﹤0.01% 734

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Assenagon Asset Management's CTMX Position: Q2 2026 in Review

Assenagon Asset Management held its CytomX Therapeutics (CTMX) position steady in Q2 2026 at 364,173 shares worth $1.37M. The position accounts for ﹤0.01% of the portfolio, ranked #921.

Assenagon Asset Management first reported a position in CTMX in Q3 2018 and has held it in 26 quarters since. The position peaked at $3.12M in Q2 2021. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Assenagon Asset Management held 364,173 shares of CytomX Therapeutics worth $1.37M as of Q2 2026.
  • Assenagon Asset Management left its CytomX Therapeutics share count unchanged in Q2 2026.
  • CytomX Therapeutics made up ﹤0.01% of Assenagon Asset Management's portfolio in Q2 2026, its #921 holding.
  • Assenagon Asset Management first reported a position in CytomX Therapeutics in Q3 2018 and has held it in 26 quarters since.
  • Assenagon Asset Management's CytomX Therapeutics position peaked at $3.12M in Q2 2021.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.